Medical Laboratories & Research
(SPEX) Initiating Spherix Analyst Coverage at Outperform
We are initiating coverage of Spherix, Inc. (SPEX) with an Outperform rating and price target of $3.50 per share. We are optimistic about D-tagatose, a functional sweetener and a naturally occurring L-epimer of D-Fructose currently under phase III development for the treatment...
9Feb2010 | vitalstocks | 0 comments | Continued(ARRY) Array BioPharma Incorporated Reports Lower Second Quarter Loss
Array BioPharma Inc’s (ARRY) second quarter fiscal 2010 net loss came in at $21.8 million, or 44 cents per share, which was lower than the Zacks Consensus Estimate of a net loss of 55 cents. The company suffered a loss of $37.8 million, or 79 cents a share, in the year-ago...
2Feb2010 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Beats Expectations – Guides In-Line
Quest Diagnostics’ (DGX) fourth quarter earnings per share of 97 cents beat both the Zacks Consensus Estimate by a penny and the 87 cents reported in the year-ago period. Revenues for the quarter increased 2.7% to $1.8 billion. Clinical testing revenues, which account for most...
25Jan2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health Announces Commercial Availability Of Its Oncotype DX Colon Cancer Test
Recently, Genomic Health, Inc. (GHDX) announced the global commercial availability of its Oncotype DX colon cancer test. The 12-gene diagnostic test aims to predict individual recurrence risk in stage II colon cancer patients after surgery. The Genomic Health test is the first...
23Jan2010 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health Provides Revenue Guidance
Genomic Health, Inc. (GHDX) announced recently that it is confident of meeting the annual revenue guidance for the fiscal year 2009, ended Dec 31. The company expects to report revenues of $149.5 million for fiscal 2009. This represents a 35% increase on revenues of $110.6 million...
8Jan2010 | vitalstocks | 0 comments | Continued(BRLI) Bio-Reference Labs – Earnings Estimates Are Rising
Bio-Reference Laboratories (BRLI) is setting new 52-week highs following its record-breaking quarter. Company Description Bio-Referance Laboratories, Inc provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan area. The company...
30Dec2009 | vitalstocks | 0 comments | Continued(GXDX) Genoptix, Inc. – Sales Were up 58% From Last Year
Genoptix, Inc. (GXDX) continues to pressure its 52-week high as shares ride a trend line that began this summer higher. The company’s better than expected third-quarter results, reported on Nov 5, also helped fuel optimism. Company Description Genoptix, Inc. provides specialized...
16Dec2009 | vitalstocks | 0 comments | Continued(ARRY) Array BioPharma Sees Positive Results for ARRY-380
Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the 2009 San Antonio Breast Cancer Symposium. The study...
14Dec2009 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health, Inc Reveals Oncotype DX Data
Genomic Health, Inc. (GHDX) announced that positive results were published in the journal, The Lancet Oncology, from a study of the company’s growth engine, Oncotype DX, in postmenopausal women suffering from node-positive, estrogen receptor-positive breast cancer. The study...
11Dec2009 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health Third Quarter Loss Narrows
Genomic Health Inc. (GHDX) suffered a third quarter loss of 2 cents per share, which was better than the Zacks Consensus Estimate of a loss of 9 cents. The company suffered a loss of 11 cents in the prior-year period. Total revenues for the quarter came in at $39.5 million, compared...
8Nov2009 | vitalstocks | 0 comments | Continued(DGX) Quest Diagnostics Outperforms – Raises Outlook
Quest Diagnostics’ (DGX) third quarter earnings per share of $1.02 beat the Zacks Consensus Estimate of 96 cents and 86 cents reported in the year ago period. Revenues for the quarter increased 3.9% to $1.9 billion. Clinical testing revenues, which account for most of Quest’s...
21Oct2009 | vitalstocks | 0 comments | Continued(GHDX) Genomic Health’s Results Reveal Oncotype DX Utility
Recently, Genomic Health Inc. (GHDX) announced data which confirmed that manual micro dissection (dissection of tissue or cells under the microscope) of biopsy cavities is essential for the accurate assessment of recurrence risk in patients with early-stage breast cancer. Genomic...
14Oct2009 | vitalstocks | 0 comments | Continued(ARRY) Setback for Array BioPharma’s Drug
Last week, Array BioPharma (ARRY) announced that its most advanced, wholly-owned MEK inhibitor, ARRY-162, which was being developed to treat rheumatoid arthritis patients, failed to achieve a better response than placebo in a mid-stage trial. The study was designed to assess...
8Sep2009 | vitalstocks | 0 comments | Continued(GHDX) Good News for Genomic Health
Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health’s Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options...
4Sep2009 | vitalstocks | 0 comments | Continued(ARRY) Array Meets Expectations
Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last...
20Aug2009 | vitalstocks | 0 comments | Continued(BRLI) Bio-Reference Laboratories Inc. – In spite of the weak economy, revenue was up 16% from last year
Bio-Reference Laboratories Inc. (BRLI) is posting impressive gains in response to strong revenue growth and expanding margins. Company Description Bio-Reference Laboratories, Inc provides clinical laboratory testing services such as blood and urine analysis in the New York metropolitan...
23Jul2009 | Shawn | 0 comments | Continued(DGX) Quest Diagnostics Incorporated – Growth And Income – Zacks Rank Buy
Quest Diagnostics Incorporated (DGX) recently delivered strong first-quarter results. Earnings per share of 89 cents topped the year-prior 72 cents and exceeded analysts’ expectations by 8.5%. Company Description Quest Diagnostics Incorporated provides diagnostic testing,...
30Apr2009 | vitalstocks | 0 comments | Continued(BRLI) Bio-Reference Laboratories – This was the second consecutive quarter that the company has surprised and beat estimates
Bio-Reference Laboratories, Inc. (BRLI) share price has been rallying since the company reported excellent fourth-quarter and full-year results last week. The next-year estimate has held steady, pegged at $1.48 per share, a n 8.5% earnings growth projection. Company Description Bio-Reference...
26Dec2008 | Shawn | 0 comments | Continued